[Penoscrotal aggressive angiomyxoma].

Aggressive angiomyxoma denotes an extremely infrequent mesenchymal tumour. In virtually every case it involves genital, pelvic or perineal female structures. Cases involving male patients are extremely rare.

[Primary mucinous adenocarcinoma of the renal pelvis--adicional case report].

Mucinous adenocarcinoma of the renal pelvis may be classified as among the rarest neoplasms of the genitourinary tract. Until the present moment just a few dozen cases have been reported previously. Despite the known association with chronic inflammatory conditions of the upper urinary tract, the exact pathogenesis remains unknown.

Colonoscopy completion in a large safety net health care system.

Background & Aims: Anecdotally, patients in safety net health care systems have difficulty completing screening and diagnostic colonoscopies, but this is poorly characterized. It is important to understand this phenomenon to improve low rates of colorectal cancer screening in vulnerable populations and to ensure that patients with signs and symptoms complete medically indicated colonoscopic evaluations.

Methods: We performed a 6-month retrospective review of outpatient endoscopy laboratory scheduling and procedure logs and electronic medical records at Denver Health Medical Center (DHMC), a large safety net health care system, to describe rates and sociodemographic predictors of colonoscopy nonattendance and inadequate (fair/poor) bowel preparation.

Inhibiting myosin light chain kinase induces apoptosis in vitro and in vivo.

Previous short-term studies have correlated an increase in the phosphorylation of the 20-kDa light chain of myosin II (MLC20) with blebbing in apoptotic cells. We have found that this increase in MLC20 phosphorylation is rapidly followed by MLC20 dephosphorylation when cells are stimulated with various apoptotic agents. MLC20 dephosphorylation is not a consequence of apoptosis because MLC20 dephosphorylation precedes caspase activation when cells are stimulated with a proapoptotic agent or when myosin light chain kinase (MLCK) is inhibited pharmacologically or by microinjecting an inhibitory antibody to MLCK.